Advertisement

Expanded Patient Access to Varenicline Solution

Oyster Point Pharma Inc. this week announced the expansion of patient access to varenicline solution (Tyrvaya) nasal spray.

According to the company, its expanded patient access programs include more eligible patients with dry eye disease.

Oyster Point Pharma Inc. this week announced the expansion of patient access to varenicline solution (Tyrvaya) nasal spray and provided an update on the commercial performance of TYRVAYA in the United States.

The company noted that it continues to expand access to varenicline solution for patients with dry eye disease. As of July 2022, varenicline solution is now covered by commercial prescription drug plans managed by the nation’s top three pharmacy benefit manager group purchasing organizations.

The company in July expanded patient access programs to include more eligible patients. For further details, please see the company’s patient access website at www.tyrvaya-pro.com.

According to the company, it continues to expect to further expand access to varenicline solution with coverage for Medicare Part D patients in 2023, and as early as Q4 2022.

The expansion of patient access to varenicline solution comes as the company continues to build upon its launch success. The company also noted that since its July 1 launch, varenicline solution prescriptions have already been written by approximately 7400 eye care prescribers (ECPs) out of the approximately 21,000 total ECPs targeted by the company’s field-based sales resources.

Advertisement

Moreover, the company noted that based on third-party data, among ECPs who have written a commercial varenicline solution prescription, varenicline solution has reached approximately 21% market share of commercial new-to-brand prescriptions (NBRx) as of the week ending July 1, 2022, driven by strong utilization among ECPs. Notably, this result was achieved in just eight months since the launch of varenicline solution in the U.S.

“We are very pleased with the continuing progress in securing commercial coverage for TYRVAYA,” said Jeffrey Nau, PhD, MMS, president and CEO of Oyster Point Pharma. “We are encouraged by the overwhelmingly positive feedback received to date from patients and eye care professionals alike. We recognize that despite growing commercial coverage for TYRVAYA, some patients who suffer from dry eye disease may also have insufficient insurance coverage or insurance plans with high deductibles and/or co-insurance.”

Nau explained that the expanded patient access program aligns with the company’s commitment to optimize access to varenicline solution for as many eligible patients as possible.

This article originally appeared on Ophthalmology Times.


Advertisement
Advertisement